BIO of Florian Kongoli

X close

Dr. Florian Kongoli holds 3 degrees: a Bachelor of Science, a Master of Science/University of Montreal, Canada and a Doctor of Science Degree/Tohoku University, Japan. Since 1996 he is CEO of FLOGEN Technologies Inc.,(www.flogen.com) a Sustainable High Tech applied research institute
incorporated in Canada and USA that today have offices and representations in more than 15 Countries around the the world while carrying out high tech projects in more than 40 countries.

Since 2007 he is Chairman of FLOGEN STAR OUTREACH (www.flogen.org), a not-for-profit organization dedicated to (1) achieving sustainability through science and technology, (2) raising the profile of science and engineering in the society and (3) properly honoring scientists and engineers.

Since 2003 Dr Kongoli has been President of the Organizing Committee of the Sustainable Industrial Processing Summits (SIPS) held every year in several countries around the world with an average participation of 500 authors from academia, industry, government and the entrepreneurship world representing an average of 80 countries.

Dr Kongoli has about 25 years of rich scientific and applied technology experience through direct involvement in numerous invited engagements in all continents. He has managed, involved, or actively participated in about 200 projects, 40 types of reactors, 10 industries, in 45 countries and in 6 continents. Dr. Kongoli has published 113 books and more than 200 scientific articles. He has delivered in numerous countries around the world about 220 plenary, keynote and invited presentations as well as articles, technical reports and research presentations. He has served in many leadership positions in national and international organizations and in many Professional Award Councils such as the Industrial Achievement Award Committee of International Federation of Automatic Control. He is Editorial Board member of several International Journals.

He is an elected Honorary Member of the Lorraine Academy of Sciences and Elected Member of Euro Mediterranean Academy of Arts and Sciences. He was awarded in 2017 the title "The Environmental Tech CEO of the year 2017" by CEO-Monthly UK magazine. He was awarded Certificate of Appreciation in recognition of his contribution toward sustainable development through FLOGEN Sustainability Framework by Tomas Bata University in Zlin (Czech Republic)/Faculty of Applied Informatics. He is honorary Citizen of Rio de Janeiro and Laureate of Gold Medal of the City of Nancy, France. In 2022 he was honored by the Congressman elect of Rio de Janeiro State, Alan Lopes, who will propose to the State Congress to adopt FLOGEN Sustainability Framework developed by Dr. Florian Kongoli in the state law for evaluating any proposed public or private project in the state. Also, in 2022 he was invited to give the Opening Sustainability Plenary Lecture at the United Nation Headquarters in Geneva, Switzerland, on 11 February 2022 about FLOGEN Sustainability Framework at the International Year of Glass 2022.

He has participated in business and government delegations in numerous countries accompanying Prime Ministers, Ministers and other government officials.
A more detailed biography can be found at: http://www.flogen.com/elt/pdf/Kongoli_Short-CV.pdf

www.flogen.org/

BIO of Stephan Buchmann

X close

Stephan Buchmann studied Pharmaceutical Sciences at the University of Basel where he also received his PhD in 1987. Thereafter he worked in Pharmaceutical R&D at Hoffmann-La Roche AG for several years, on transdermal drug delivery, preformulation and early formulation development. From 1997 to 2000 he was responsible for the Pharmaceutical Development at Spirig Pharma AG, Switzerland, developing liquid and semisolid topical products as well as oral solid dosage forms, including scaling-up under GMP. After that he joined Actelion Pharmaceuticals, as a Director, Senior Group Leader being responsible for setting up and leading the area of preformulation, i.e. compound characterisation with regard to physicochemical and solid state properties, as well as development of preclinical formulations which were used for pharmacodynamic, pharmacokinetic and toxicological trials in vivo in research and preclinical development. After the demerger of Actelion Pharmaceuticals and foundation of Idorsia Pharmaceuticals in 2017, he was responsible for development and manufacturing of preclinical formulations at Idorsia Pharmaceuticals.

In January 2020 he retired from his job and responsibilities in the pharmaceutical industry and became an “Amateur Historian” as he had always been interested in history. The main focus is on the local history of Basel, including its Pharmaceutical Industry like Roche and Novartis, as well as history of pharmaceutics in general.

www.flogen.org/

BIO of Georgios Imanidis

X close

Georgios Imanidis is head of the Institute of Pharma Technology at the School of Life Sciences, University of Applied Sciences Northwestern Switzerland and is full Professor at the University of Applied Sciences and titular Professor at the Faculty of Science of the University of Basel. In his current position, he established the Institute and introduced de novo research and teaching in Pharma Technology at the School of Life Sciences covering technical and biopharmaceutical aspects of the field. He developed the study curriculum with emphasis in pharmaceutical technology, established laboratory facilities for teaching and research encompassing chemical and biological drug entities, recruited six faculty members and built the working group of the Institute currently comprising 35 members. In its brief existence the Institute has established broad expertise and attained national and international recognition as a center of competence for pharmaceutical technology.

Prof. Imanidis developed and implemented mathematical modeling of physicochemical transport processes for the evaluation and prediction of drug delivery, drug absorption and performance of intestinal drug formulations in biorelevant in vitro models with accompanying media and preclinical in vivo models. This concept was implemented in Caco-2 cell culture-based investigation of cellular pharmacokinetics comprising phase I and phase II metabolism and influx and efflux of drug and metabolite and in preclinical animal model-based investigation for elucidating systemic drug exposure and intestinal targeted delivery, respectively.

He investigated drug formulation and delivery in (trans)dermal administration for treatment and prevention of skin disease and introduced mathematical model-based assessment of biological effect and formulation performance. The later was based on site-of-action active moiety concentration in cutaneous tissue in in vitro and in vivo model systems and viscoelastic formulation properties and formulation transformation providing a mechanistic understanding and predictability of the effect of medicinal product application.

www.flogen.org/

BIO of Ibrahim Karim

X close

Born in Cairo 1942, Graduate (Arch. Diploma, PhD) ETH Zürich.
CEO ALEMARA Consulting House (founded 1939).
Founder of BioGeometry Physics of Quality 1972.
President of BioGeometry companies, Egypt, Switzerland, Canada
Prof.Arch. Helwan Univ. (1972, 1975), 15 May Eng. Academy (2000-5)
Post-graduate Supervising Prof. Cairo University (2005-present), PhD research in BioGeometry applications in electromagnetic stress, depression, Autism, ADHD.
Advisor to Minister of Health, EG (1970-1985)
Advisor to Minister of Culture, EG (1982-1985)
Advisor to Minister of. Tourism, EG (1985-1990)
Industrialization of Egyptian tourism-Tourist plan Red Sea
Advisor to Minister of Scientific research, Head of BioGeometry research unit at National Research Center, EG, (1990-1994)
Environmental electrosmog projects w. Swisscom in Hemberg 2003, Hirschberg 2007, Switzerland. Chosen by Swiss Anzeiger magazine as Man of the year 2005.
Environmental Award University of 6 October Cairo2007
Completely chemical free chicken farming projects at Nutrinor, Alma, Quebec, Canada ( 2012-2018).
Author: Back to a future for Mankind, BioGeometry Signatures, Hidden Reality, Amazon.

www.flogen.org/

BIO of Go Kimura

X close

EDUCATION
In 2012, Dr. Go Kimura received a Ph.D. from the Faculty of Pharmacy, University of Basel ("Design of pharmaceutical tablet formulation for a low water soluble drug: Search for the critical concentration of starch based disintegrant applying percolation theory and F-CAD (Formulation-Computer Aided Design) ").
In 1999, he received Master of Pharmacy at Kyoto Pharmaceutical University.
In 1997, he registered as Pharmacist.

EMPLOYMENT HISTORY and RELATED ACTIVITIES
In 2021, he became Senior director of Formulation R&D laboratory at Shionogi & Co., Ltd.
In 2020, he became Senior director of Manufacturing technology Unit at Shionogi Pharma Co., Ltd and Outside director Shionogi Business Partner Co., Ltd.
In 1999, he joined Shionogi & Co., Ltd. and worked in Formulation R&D Laboratory.
In recent years, focusing the pharmaceutical formulation researches on "Speeding up product development based on science", "Further utilizing the continuous manufacturing technology", "Creating new value for products using the spray freeze-drying technology", "Developing medical devices associated with vaccine product development" and “Development of sustained-release oral and injectable formulations.”

AWARDS
In 2015, he received Asahi Kasei Young Investigator Award from The Academy of Pharmaceutical Science and Technology, Japan (APSTJ).
In 2014, he received Postdoctoral Presentation Award from The APSTJ.

www.flogen.org/

BIO of Gregory Knipp

X close

Dr Gregory T. Knipp is an Associate Professor of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, and serves as the Associate Director of the Dane O. Kildsig Center for Pharmaceutical Processing Research and the Director of the Purdue Translational Pharmacology CTSI Core Facility. He received a B.S. in Biochemistry from Rutgers in 1988. He then worked in the Physical Pharmacy Department at Bristol-Myers Squibb until 1991, prior to returning to graduate school. In 1997, he received a Ph.D. in Pharmaceutical Chemistry from The University of Kansas, and then performed postdoctoral research in the Department of Molecular and Integrative Physiology at The University of Kansas Medical Center until 1999. After his postdoctoral studies, he became an Assistant Professor in the Department of Pharmaceutics in the Ernest Mario School of Pharmacy at Rutgers, the State University of NJ. In 2006, his laboratory moved to the Department of Industrial and Physical Pharmacy at Purdue University. His current research interests include the molecular and functional characterization of oligopeptide and fatty acid transporters, the effect of xenobiotics on placental fatty acid homeostasis and fetal development, and the effects of dosage form variation on clinically-relevant performance in the juvenile and adult porcine models.

www.flogen.org/

BIO of Michael Makanga

X close

Dr Michael Makanga, MD PhD FRCP: Global Health EDCTP3 Joint Undertaking Executive Director.

Dr Makanga is a clinician-scientist with about 30 years of professional experience of working on health and poverty-related infectious diseases in Africa. This includes 23 years of work experience on medical product development and clinical regulatory activities. He holds a Medical Degree from Makerere University, Uganda; a Master's Degree at the University of Liverpool, and a PhD Clinical Pharmacology at the Liverpool School of Tropical Medicine, United Kingdom. He is also a Fellow of the Royal College of Physicians of Edinburgh, Scotland.

Dr Makanga is the Executive Director of Global Health EDCTP3 Joint Undertaking, and former Executive Director of the EDCTP-Association. Prior to joining EDCTP, Dr Makanga was first in clinical practice and academia, and later clinical research and research management. Moreover, he has served in various scientific and policy advisory boards for international product development, philanthropic organizations, the World Bank and pharmaceutical companies involved in developing medicinal products for poverty-related and neglected diseases.

www.flogen.org/

BIO of Natalia Menshutina

X close

Doctor of Technical Sciences, Professor, Head of the Department of Chemical and Pharmaceutical Engineering, Mendeleev University of Chemical Technology of Russia, Academician (Full Member) of The Swiss Academy of Engineering Sciences (SATW), Academician (Full member) of the Russian Academy of Engineering.

Natalia Menshutina is a well-known specialist in the field of mathematical modeling, chemical and pharmaceutical technology. Scientific research and publications are devoted to development of the theory and practice of chemical and pharmaceutical technology processes, supercritical fluid technology, creation of new nanomaterials, computer and mathematical modeling, digitalization of individual processes and production.

Research in recent years has been related to developments in the field of pharmaceutical technologies. Natalia Menshutina has connections with both foreign and Russian pharmaceutical companies. Areas of interest include the development of solid dosage forms, nasal and inhaled drugs against stroke, depression and inflammation. Recent work is related to the study of nasal drug delivery systems for targeted delivery of drugs to the brain.

Natalia Menshutina actively cooperates with universities and pharmaceutical enterprises in Europe, China and Russia.

www.flogen.org/

BIO of Peter Swaan

X close

Peter W. Swaan, Ph.D., M.Pharm., began his tenure as the eighth dean of the University of Florida College of Pharmacy on Dec. 1, 2022. Swaan previously served as the associate dean for research and advanced graduate education as well as a professor and chair in the department of pharmaceutical sciences at the University of Maryland School of Pharmacy. While at Maryland, he was appointed a distinguished university professor in recognition of his extraordinary leadership and significant contributions to the pharmaceutical sciences.

Swaan is well connected to many of the nation’s largest and most prestigious pharmacy colleges. His academic and professional career includes stops at the University of Michigan; the University of California, San Francisco; the Ohio State University; and the University of Maryland. All four of these pharmacy colleges are featured in the top 15 of the U.S. News & World Report best pharmacy college rankings.

A highly cited researcher, Swaan has published more than 150 original research articles. He has been continuously funded by the National Institutes of Health since 1998 and has secured more than $25 million in grant funding during his career. His research focuses on all aspects of transporters in drug targeting and delivery, pharmacokinetics and pharmacodynamics, with his major contributions to this research area involving the application of transporters as targets for prodrugs. He has pioneered the use of computational techniques to determine the structural requirements of membrane transporters, which has paved the way for the discovery of novel substrates and inhibitors. He also holds several U.S. patents on these and related technologies.

Since 2015, Swaan has chaired the Board of Grants for the American Foundation for Pharmaceutical Education, or AFPE. He has also chaired multiple committees within the American Association for Pharmaceutical Scientists and served on multiple NIH study sections. More than two dozen master’s and Ph.D. students have trained under his guidance, and in July 2022, he was awarded the AFPE William M. Heller Mentor of the Year Award.

www.flogen.org/

BIO of Marcel Tanner

X close

Prof Marcel Tanner is President of the Swiss Academy of Arts and Sciences and a board member of Foundation Botnar. He is Director Emeritus of the Swiss Tropical and Public Health Institute (Swiss TPH) and also a Professor Emeritus of Epidemiology and Medical Parasitology at the University of Basel. His research interests include the fields of global health, epidemiology, health systems, infectious diseases and public health. Over the course of his research career, he has lived and worked extensively in Africa and Asia. He headed the Tropical Institute in Ifakara, Tanzania, which eventually grew into the Ifakara Health Institute. Among his notable work, Prof Tanner was instrumental in the development of malaria vaccines. He also implemented large programmes in the field of health planning and the training of health workers on behalf of the Swiss and Tanzanian governments. He is the author of over 700 publications, 51 book chapters and numerous reports for governments and international organizations. He obtained his PhD in medical biology from the University of Basel and a master’s in public health from the University of London, UK.

www.flogen.org/

BIO of Hassan Tarabishi

X close

Dr. Hassan Tarabishi holds 3 degrees: a bachelor of science in pharmacy and pharmaceutical chemistry/Damascus University Syria, Diploma in Pharmaceutical Technology and Biopharmacy and Ph.D. in Pharmaceutical Technology and Industrial Pharmacy/Basle University Switzerland.

From 1996 -1999 he worked by F. Hoffmann-La Roche Ltd., Switzerland with focus on sterile pharmaceuticals and its infra structure like clean rooms, water, air and gases. In 1998 he was chosen to represent Switzerland at the working party of the European Pharmacopoeia Commission for “Water for Injection” as member of the “Water Experts Group” of the Swiss Pharmacopoeia Commission. In these efforts he aimed to harmonize standards of pharma waters between different pharmacopeia.

Since 2000 in collaboration with international European companies he supported many projects in the emerging and fast developing pharmaceutical industry in the Middle East with focus on sterile pharmaceuticals and pharma water, In 2003 he established Shamra Pharma in Syria for manufacturing sterile dental anesthetic cartridges.

Since 2005 established Somicon ME in UAE besides co-establishing many other companies in UAE, KSA with activities in water desalination, treatment, recycle and reuse providing environment friendly solutions and chemicals to local water authorities in the region.

Since 2019 developed innovative water based wide spectrum and non-hazardous disinfectants.

Dr. Tarabishi, has more than 25 years’ experience in pharmaceutical formulations, GMP, validation, sterile pharmaceutical production and supportive infrastructure, pharmaceutical water. Cartilage Biotechnology and Bioengineering, water desalination, purification and waste water treatment and recycle. Membrane and filtration technology. Water treatment chemicals and disinfectant production.

Dr. Tarabishi is Member of the Swiss Association for Industrial Pharmacist "GSIA", Switzerland, Member of the working party of the European Pharmacopoeia Commission for “ Water for Injection” in Strasbourg, France, Member of the “Water Experts Group” of the Swiss Pharmacopoeia Commission, Member of German Society for Water Desalination. GMP- expert by the German TÜV certification body for ISO 9000 & ISO 14000.

www.flogen.org/